Navigation Links
Stantum Offering Demo, Evaluation & Development Board Based on Its Patented Resistive Multi-Touch Technology
Date:9/23/2008

First Such Board on the Market, Stantum's SMK Series Will Let Vendors Cost-Effectively Develop Their Own Resistive Multi-Touch Applications

SAN DIEGO, Sept. 23 /PRNewswire/ -- Stantum Technologies (http://www.stantum.com), a pioneer developer of multi-touch sensing technology, today introduced a demo, evaluation and development board based on its patented PMatrix(TM) resistive multi-touch technology, which lets users simultaneously move an unlimited number of fingers, nails or utensils (such as styli) on a screen.

The first such board on the market, the new SMK series enables vendors and OEMs to evaluate the performance of Stantum's technology and begin developing their own resistive multi-touch applications, thanks to a user-friendly interface compatible with Windows, MAC OS and Linux.

"Stantum is demonstrating that -- contrary to widespread misbelief -- multi-touch is possible with a cost-effective resistive touch-panel platform," said Chris Crotty, director of small and medium displays research at DisplaySearch, a leading provider of information, consulting and conferences on the display supply chain and display-related industries. "With this groundbreaking announcement, Stantum is combining the best of both worlds by offering the features of projected capacitive multi-touch with the lower cost and widespread availability of resistive touch technology."

Added Guillaume Largillier, Stantum's co-founder and CEO: "Our SMK series is the smart multi-touch development kit that the consumer electronics and other industries have long anticipated. It gives manufacturers developing their hardware and applications a great opportunity to assess the huge advantages that multi-touch capability can offer, especially when it uses resistive technology."

SMK boards come with either a 2.5- or 3.5-inch touch-panel sensor; a multi-touch controller; Stantum's Lemurofon software, for demonstrating simple multi-touch applications like games, picture zoom in and out, and keyboard; and a USB port.

SMK multi-touch evaluation and development boards are scheduled to be available Oct. 1. Inquiries can be made via Stantum's web site at http://www.stantum.com/spip.php?page=inquiry.

About Stantum Technologies

Stantum Technologies (formerly JazzMutant) has pioneered multi-touch technologies since its founding in 2002 by Guillaume Largillier and Pascal Joguet. The following year, it developed the world's first multi-touch screen that could track an unlimited number of fingers at once and in 2005 launched Lemur, the first multi-touch product available on the market. Today, Stantum's technology portfolio and product offerings cover every aspect of multi-touch interaction, including sensor design, multi-touch controllers, intellectual property cores, software integration, and application programming interfaces. Stantum is headquartered in Bordeaux, France, with the U.S. accounting for about one-third of its worldwide sales.

Editorial Contact

Neal Leavitt

Leavitt Communications

760-639-2900 or 760-212-9112

neal@leavcom.com


'/>"/>
SOURCE Stantum
Copyright©2008 PR Newswire.
All rights reserved

Related biology news :

1. Positron emission tomography superior to standard evaluation tools in measuring treatment response
2. Gender, coupled with diabetes, affects vascular disease development
3. New target for anti-flu drug development
4. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
5. KAUST and American University in Cairo to collaborate on research and academic development
6. Old developmental pathways spawn revolutionary evolutionary changes
7. NIST announces 56 new awards for innovative technology research and development
8. Progress Against Malaria: Developments on the Horizon
9. Flu vaccine in painless skin patches under development at Emory, Georgia Tech with NIH grants
10. Biopharmaceutical infrastructure key to lower drug development costs
11. Study identifies pathway required for normal reproductive development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint Inhibitors ... Rising Market Are you interested in the ... revenues for checkpoint inhibitors. Visiongain,s report gives those ... product and national level. Avoid falling behind ... progress, opportunities and revenues those emerging cancer therapies ...
(Date:2/1/2016)...  Today, the first day of American Heart Month, ... a first of its kind workplace health solution that ... the first application of Watson ... and Welltok will create a new offering that combines ... delivered on Welltok,s health optimization platform. The effort is ...
(Date:1/25/2016)... 2016  Glencoe Software, the world-leading supplier of image ... will provide the data management solution OMERO Plus for ... Photo - ... Phenotypic analysis measures the characteristics and behavior ... between states such as health and disease, the presence ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... Massachusetts , February 4, 2016 - New FDA ... - New FDA action date of July 22, ... of July 22, 2016   - ... U.S. in the past decade indicated for the treatment of signs and symptoms ... Lifitegrast has the potential to be the only product approved in the U.S. ...
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific Instruments will showcase ... demos and poster sessions, and present on the analysis of mycotoxins and medical ... 6 to 10 at the Georgia World Congress Center in Atlanta, Georgia. ...
(Date:2/4/2016)... 2016 Beike Biotechnology, the Shenzhen ... a ceremony in late 2015 to mark their successful ... 2016. --> --> ... Personalized Cell Therapy" was hosted by the Shenzhen Cell ... subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... PARK, Calif. , Feb. 4, 2016   DelMar ... biopharmaceutical company focused on the development and commercialization of new ... 18 th Annual BIO CEO & Investor Conference ... in New York, NY . ... an update on the ongoing clinical trial of VAL-083 ...
Breaking Biology Technology: